KR20200071573A - Antiviral Composition for Middle East Respiratory Syndrome Coronavirus Using Chloroxine or Analogues Thereof - Google Patents
Antiviral Composition for Middle East Respiratory Syndrome Coronavirus Using Chloroxine or Analogues Thereof Download PDFInfo
- Publication number
- KR20200071573A KR20200071573A KR1020180159448A KR20180159448A KR20200071573A KR 20200071573 A KR20200071573 A KR 20200071573A KR 1020180159448 A KR1020180159448 A KR 1020180159448A KR 20180159448 A KR20180159448 A KR 20180159448A KR 20200071573 A KR20200071573 A KR 20200071573A
- Authority
- KR
- South Korea
- Prior art keywords
- respiratory syndrome
- middle east
- east respiratory
- composition
- food
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 title claims abstract description 21
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 20
- WDFKMLRRRCGAKS-UHFFFAOYSA-N chloroxine Chemical compound C1=CN=C2C(O)=C(Cl)C=C(Cl)C2=C1 WDFKMLRRRCGAKS-UHFFFAOYSA-N 0.000 title abstract description 6
- 229960004736 chloroxine Drugs 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 42
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 239000000651 prodrug Substances 0.000 claims abstract description 5
- 229940002612 prodrug Drugs 0.000 claims abstract description 5
- 239000012453 solvate Substances 0.000 claims abstract description 4
- 235000013305 food Nutrition 0.000 claims description 24
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 12
- 208000025370 Middle East respiratory syndrome Diseases 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 abstract description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 14
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 235000013373 food additive Nutrition 0.000 description 11
- 239000002778 food additive Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 241000711573 Coronaviridae Species 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 101150013191 E gene Proteins 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- -1 fatty acid esters Chemical class 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000000241 respiratory effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 244000309467 Human Coronavirus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 230000005727 virus proliferation Effects 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
- 229960003677 chloroquine Drugs 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960004525 lopinavir Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000021096 natural sweeteners Nutrition 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000006201 parenteral dosage form Substances 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- ZDASUJMDVPTNTF-UHFFFAOYSA-N 5,7-dibromo-8-quinolinol Chemical compound C1=CN=C2C(O)=C(Br)C=C(Br)C2=C1 ZDASUJMDVPTNTF-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- ADJQQSUBKRASQN-UHFFFAOYSA-N 7-bromo-5-chloroquinolin-8-ol Chemical compound C1=CN=C2C(O)=C(Br)C=C(Cl)C2=C1 ADJQQSUBKRASQN-UHFFFAOYSA-N 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000112287 Bat coronavirus Species 0.000 description 1
- 241000008904 Betacoronavirus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- AZJUFRDUYTYIHV-NKFKGCMQSA-N Dibenzoyl Thiamine Chemical compound C=1C=CC=CC=1C(=O)OCC\C(SC(=O)C=1C=CC=CC=1)=C(/C)N(C=O)CC1=CN=C(C)N=C1N AZJUFRDUYTYIHV-NKFKGCMQSA-N 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004301 calcium benzoate Substances 0.000 description 1
- 235000010237 calcium benzoate Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- MCFVRESNTICQSJ-RJNTXXOISA-L calcium sorbate Chemical compound [Ca+2].C\C=C\C=C\C([O-])=O.C\C=C\C=C\C([O-])=O MCFVRESNTICQSJ-RJNTXXOISA-L 0.000 description 1
- 239000004303 calcium sorbate Substances 0.000 description 1
- 235000010244 calcium sorbate Nutrition 0.000 description 1
- HZQXCUSDXIKLGS-UHFFFAOYSA-L calcium;dibenzoate;trihydrate Chemical compound O.O.O.[Ca+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 HZQXCUSDXIKLGS-UHFFFAOYSA-L 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- CTQMJYWDVABFRZ-UHFFFAOYSA-N cloxiquine Chemical compound C1=CN=C2C(O)=CC=C(Cl)C2=C1 CTQMJYWDVABFRZ-UHFFFAOYSA-N 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000002247 constant time method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 1
- 229940099364 dichlorofluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940082629 iron antianemic preparations Drugs 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000019449 other food additives Nutrition 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000004300 potassium benzoate Substances 0.000 description 1
- 235000010235 potassium benzoate Nutrition 0.000 description 1
- 229940103091 potassium benzoate Drugs 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- FJWLWIRHZOHPIY-UHFFFAOYSA-N potassium;hydroiodide Chemical compound [K].I FJWLWIRHZOHPIY-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- XSCGXQMFQXDFCW-UHFFFAOYSA-N triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 description 1
- 229960003904 triflupromazine Drugs 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Abstract
Description
본 발명은 클로록신 또는 그 유사 화합물을 이용한 중동호흡기증후군 코로나바이러스(Middle East Respiratory Syndrome Coronavirus, MERS-CoV)에 대한 항바이러스 조성물에 관한 것이다.The present invention relates to an antiviral composition for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) using chloroxine or a similar compound.
중동호흡기증후군 (MERS)은 2012년 6월 사우디아라비아에서 최초의 환자가 보고된 이래 2018년 11월까지 전세계 2260명의 환자가 발생하였고 803명의 사망자가 발생하여 치사율 35.5%의 치명적인 바이러스 감염병이다. 총 감염환자의 약 97%가 사우디아라비아, 아랍에미리트 등 중동지역에서 발생하였다. 대한민국에서도 2015년 5월부터 11월까지 총 186명의 확진 환자 및 38명의 사망자가 발생하였다. 질환의 증상은 38℃ 이상의 발열, 기침, 호흡곤란 증 일반적인 호흡기 증상과 구토, 설사 등이 있을 수 있으며, 증세가 심해지면 신부전 및 호흡부전, 패혈성 쇼크, 중증급성 하기도질환 (폐렴)으로 사망에 이를 수 있다. 특히 당뇨, 신부전 등 만성 기저질환이 있거나 면역력이 저하된 사람에게는 더욱 치명적일 수 있다.The Middle East Respiratory Syndrome (MERS) is a fatal viral infection with a fatality rate of 35.5%, resulting in 2,260 deaths worldwide and 803 deaths since November 2018 since the first patient was reported in Saudi Arabia in June 2012. About 97% of the total infected patients occurred in the Middle East, including Saudi Arabia and the United Arab Emirates. In Korea, a total of 186 confirmed cases and 38 deaths occurred from May to November 2015. Symptoms of the disease may include fever, cough, dyspnea over 38℃, general respiratory symptoms, vomiting, diarrhea, etc., and severe symptoms can lead to death due to renal failure, respiratory failure, septic shock, and severe acute respiratory disease (pneumonia). You can do this. In particular, people with chronic underlying diseases such as diabetes and kidney failure or those with reduced immunity can be more fatal.
중동호흡기증후군의 원인 병원체는 중동호흡기증후군 코로나바이러스 (MERS-CoV)로 알려져 있다. 중동호흡기증후군 코로나바이러스는 2012년 최초 발견되었을 때 HCoV-EMC로 명명되었으나 2013년 5월 국제바이러스 분류위원회에서 MERS-CoV라는 명칭으로 바뀌었다. 중동호흡기증후군 코로나바이러스는 코로나바이러스과 베타코로나바이러스속에 속하며, 약 30 킬로베이스의 게놈으로 구성된 외피가 있는 양성가닥 RNA 바이러스이다. 바이러스의 외피 표면에 발현되는 spike 단백질은 사람의 숙주세포 표면에 있는 Dipeptidyl peptidase 4 (DPP4 또는 CD26)라는 수용체를 인지함으로써 세포 내부로 침투함이 밝혀졌다.The causative agent of the Middle East Respiratory Syndrome is known as the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The Middle East Respiratory Syndrome Coronavirus was named HCoV-EMC when it was first discovered in 2012, but was renamed MERS-CoV by the International Virus Classification Committee in May 2013. The Middle East Respiratory Syndrome Coronavirus belongs to the genus Coronavirus and beta coronavirus and is a positive stranded RNA virus with an envelope composed of about 30 kilobases of genome. It has been found that the spike protein expressed on the surface of the virus envelope penetrates into cells by recognizing a receptor called Dipeptidyl peptidase 4 (DPP4 or CD26) on the surface of a human host cell.
중동호흡기증후군 코로나바이러스의 감염경로는 아직 명확하게 밝혀지지 않았으나 사우디아라비아에서 단봉낙타를 통한 감염 사례가 보고되고 있으며, 박쥐 코로나바이러스와 유전자 서열이 유사하여 박쥐, 단봉낙타, 사람으로 전파된 것으로 추정되고 있다. 대한민국의 사례에서는 중동지역 여행객이 입원한 병원내에서 사람간 밀접접촉에 의하여 감염이 크게 확산된 것으로 보고되었다. The route of infection in the Middle East Respiratory Syndrome Coronavirus has not been clearly identified, but cases of infection through dromedary camels have been reported in Saudi Arabia, and the genetic sequence is similar to that of bat coronavirus, presumed to have spread to bats, dromedaries, and humans. have. In the case of Korea, it was reported that the infection spread greatly due to close contact between people in the hospital where travelers from the Middle East were hospitalized.
Chlorpromazine, Triflupromazine, Imatinib mesylate, Dasatinib, Gemcitabine, Toremifene, Chloroquine, Lopinavir와 같은 기존의 저분자 약물이 세포 수준에서 중동호흡기증후군 코로나바이러스를 저해하는 활성이 보고되었다. 최근에는 spike에 대한 단클론항체, 세포막 융합을 억제하는 펩타이드 또한 개발 진행 중에 있다. 그러나 아직까지 중동호흡기증후군에 대하여 승인 받은 약물 및 예방 백신이 없으므로, 중동호흡기증후군 코로나바이러스 감염을 억제하고 질병치료 및 예방을 위한 약물의 개발이 매우 시급한 실정이다.Existing low molecular drugs such as Chlorpromazine, Triflupromazine, Imatinib mesylate, Dasatinib, Gemcitabine, Toremifene, Chloroquine and Lopinavir have been reported to inhibit the Middle East Respiratory Syndrome coronavirus at the cellular level. Recently, monoclonal antibodies against spikes and peptides that inhibit cell membrane fusion are also under development. However, since there are no drugs and preventive vaccines approved for the Middle East Respiratory Syndrome yet, the development of drugs for suppressing coronavirus infection in the Middle East Respiratory Syndrome and treating and preventing diseases is very urgent.
본 발명은 중동호흡기증후군 코로나바이러스에 대한 항바이러스 활성을 가지는 화합물들을 개시한다.The present invention discloses compounds having antiviral activity against Middle Eastern respiratory syndrome coronavirus.
본 발명의 목적은 중동호흡기증후군 코로나바이러스에 대한 항바이러스 조성물을 제공하는 데 있다.An object of the present invention is to provide an antiviral composition against Middle Eastern respiratory syndrome coronavirus.
본 발명의 다른 목적이나 구체적인 목적은 이하에서 제시될 것이다.Other or specific objects of the present invention will be presented below.
본 발명자들은 아래의 실시예에서 확인되는 바와 같이, 아래 화학식 1 내지 4의 화합물인 클로록신과 그 유사 화합물을 Vero (CCL-81)세포에 처리하고 중동호흡기증후군의 원인 바이러스인 중동호흡기증후군 코로나바이러스를 감염시켜 이들 화합물의 중동호흡기증후군 코로나바이러스의 증식 억제 효과를 살펴봤을 때, 화학식 3의 화합물을 제외한 나머지 화합물 모두가 중동호흡기증후군 코로나바이러스의 증식 억제 효과를 가짐을 확인하였으며, 나아가 이들 화합물 중 대표적으로 화학식 1 및 2의 화합물이 중동호흡기증후군 코로나바이러스에 감염된 Vero (CCL-81)세포에서 E 유전자 상위 영역(upstream of E gene)의 발현 정도에 미치는 영향을 살펴봤을 때에도 모두 농도 의존적으로 그 발현을 억제함을 확인하였다. 상기 E 유전자 상위 영역은 코로나 바이러스의 증식 정도를 보여주는 지표로 사용될 수 있음이 알려져 있다(Corman VM et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Eurosurveillance 2012; 17:20285). The present inventors, as confirmed in the Examples below, treated with the compounds of formulas 1 to 4 below, chloroxine and its similar compounds in Vero (CCL-81) cells, and the Middle East Respiratory Syndrome Coronavirus, the causative virus of the Middle East Respiratory Syndrome. When the effect of inhibiting the proliferation of these compounds in the Middle East Respiratory Syndrome coronavirus was examined, it was confirmed that all of the other compounds except the compound of Formula 3 have an inhibitory effect on the proliferation of the Middle East Respiratory Syndrome coronavirus, and further, these compounds are representative. As a result, when the effects of the compounds of Formulas 1 and 2 on the expression level of the upper region of the E gene in Vero (CCL-81) cells infected with the Middle East Respiratory Syndrome Coronavirus were examined in a concentration-dependent manner. It was confirmed to suppress. It is known that the upper region of the E gene can be used as an indicator showing the degree of proliferation of coronavirus (Corman VM et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Eurosurveillance 2012; 17:20285 ).
전술한 바를 고려할 때, 본 발명은 화학식 1, 화학식 2 및 화학식 4의 화합물 중 어느 하나의 화합물, 그 프로드럭, 그 용매화물 또는 그 수화물을 유효성분으로 포함하는 중동호흡기증후군 코로나바이러스에 대한 항바이러스용 조성물로 파악할 수 있다. In view of the above, the present invention is an antiviral against the Middle East Respiratory Syndrome coronavirus comprising any one of the compounds of Formula 1, Formula 2 and Formula 4, its prodrug, its solvate or its hydrate as an active ingredient. It can be grasped by the composition.
화학식 1 내지 4의 화합물은 공지의 화합물로서, 화학식 1의 화합물은 Sigma-Aldrich 社에에서 화학식 2 내지 화학식 4의 화합물은 Tokyo Chemical Industry 社에서 구입이 가능하며, 그 IUPAC 명칭과 화학식은 아래에서 확인할 수 있다. The compounds of Formulas 1 to 4 are known compounds, and the compounds of Formula 1 are available from Sigma-Aldrich, and the compounds of Formulas 2 to 4 are available from Tokyo Chemical Industry, whose IUPAC names and formulas are identified below. Can be.
<화학식 1> 5,7-Dichloro-8-quinolinol (Chloroxine)<Formula 1> 5,7-Dichloro-8-quinolinol (Chloroxine)
<화학식 2> 5,7-Dibromo-8-hydroxyquinoline<Formula 2> 5,7-Dibromo-8-hydroxyquinoline
<화학식 3> 5-Chloro-8-quinolinol<Formula 3> 5-Chloro-8-quinolinol
<화학식 4> 7-Bromo-5-chloro-8-hydroxyquinoline<Formula 4> 7-Bromo-5-chloro-8-hydroxyquinoline
본 명세서에서, "중동호흡기증후군 코로나바이러스에 대한 항바이러스"는 중동호흡기증후군 코로나바이러스의 인체 내 증식 억제, 감염 억제, 중동호흡기증후군의 예방, 치료 또는 증상 경감을 포함하는 의미이다. In the present specification, "anti-viral against the Middle East Respiratory Syndrome Coronavirus" is meant to include proliferation inhibition, infection suppression, prevention, treatment or relief of symptoms in the Middle East Respiratory Syndrome Coronavirus.
또 본 명세서에서, "프로드럭(prodrug)"은 어떤 약물을 화학적으로 변화시켜 물리적, 화학적 성질을 조절한 약물을 의미하며, 그 자체는 생리 활성을 나타내지 않지만 투여 후 체내에서 화학적 혹은 효소의 작용에 의해 원래의 약물로 바뀌어 약효를 발휘할 수 있는 약물을 의미한다.In addition, in the present specification, "prodrug (prodrug)" refers to a drug that chemically changes a certain drug to control its physical and chemical properties, and does not exhibit physiological activity itself, but does not affect the action of chemicals or enzymes in the body after administration. It means a drug that can be converted to the original drug and exert its medicinal effect.
또 본 명세서에서 "수화물(hydrate)"은 물이 결합되어 있는 화합물을 의미하며, 물과 화합물 사이에 화학적인 결합력이 없는 내포 화합물을 포함하는 의미이다.In addition, "hydrate" in the present specification means a compound to which water is bound, and includes a compound containing no chemical bond between water and the compound.
또 본 명세서에서 "용매화물"은 용질의 분자나 이온과 용매의 분자나 이온 사이에 생긴 화합물을 의미한다.In addition, in this specification, "solvate" means a compound formed between a molecule or ion of a solute and a molecule or ion of a solvent.
또 본 명세서에서 "유효성분"이란 단독으로 목적하는 활성을 나타내거나 또는 그 자체는 활성이 없는 담체와 함께 활성을 나타낼 수 있는 성분을 의미한다.In addition, in the present specification, "active ingredient" refers to a component that can exhibit a desired activity alone or itself can exhibit activity with an inactive carrier.
본 발명의 조성물에서 그 유효성분은 항바이러스 활성을 나타낼 수 있는 한, 그 구체적 용도, 제형 등에 따라 임의의 양(유효량)으로 포함될 수 있는데, 통상적인 유효량은 조성물 전체 중량을 기준으로 할 때 0.0001 중량 % 내지 20.0 중량 % 범위 내에서 결정될 것이다. 여기서 "유효량"이란 그 적용 대상인 포유동물 바람직하게는 사람에게 의료 전문가 등의 제언에 의한 투여 기간 동안 본 발명의 조성물이 투여될 때, 중동호흡기증후군 코로나바이러스 감염증의 치료, 예방, 증상 경감 효과 등 의도한 의료적·약리학적 효과를 나타낼 수 있는, 본 발명의 조성물에 포함되는 유효성분의 양을 말한다. 이러한 유효량은 당업자의 통상의 능력 범위 내에서 실험적으로 결정될 수 있다. The active ingredient in the composition of the present invention can be included in any amount (effective amount) according to the specific use, formulation, etc., as long as it can exhibit antiviral activity, the typical effective amount is 0.0001 weight based on the total weight of the composition % To 20.0% by weight. Herein, the term "effective amount" is intended to treat, prevent, and relieve symptoms of coronavirus infection in the Middle East Respiratory Syndrome when the composition of the present invention is administered to a mammal, preferably a person, to which a target is applied, according to a recommendation of a medical professional or the like. It refers to the amount of active ingredient contained in the composition of the present invention, which can exhibit a medical and pharmacological effect. Such an effective amount can be determined empirically within the ordinary skill in the art.
본 발명의 조성물은 다른 구체적인 양태에 있어서는 약제학적 조성물로 파악될 수 있다.The composition of the present invention may be identified as a pharmaceutical composition in other specific embodiments.
본 발명의 약제학적 조성물은 유효성분 이외에 약제학적으로 허용되는 담체를 포함하여 당업계에 공지된 통상의 방법으로 투여 경로에 따라 경구용 제형 또는 비경구용 제형으로 제조될 수 있다. 여기서 "약제학적으로 허용되는" 의미는 유효성분의 활성을 억제하지 않으면서 적용(처방) 대상이 적응 가능한 이상의 독성을 지니지 않는다는 의미이다.The pharmaceutical composition of the present invention may be prepared in an oral dosage form or a parenteral dosage form according to the route of administration by a conventional method known in the art, including a pharmaceutically acceptable carrier in addition to the active ingredient. Here, "pharmaceutically acceptable" means that the target of application (prescription) has no toxicity beyond adaptability without inhibiting the activity of the active ingredient.
본 발명의 약제학적 조성물이 경구용 제형으로 제조될 경우, 적합한 담체와 함께 당업계에 공지된 방법에 따라 분말, 과립, 정제, 환제, 당의정제, 캡슐제, 액제, 겔제, 시럽제, 현탁액, 웨이퍼 등의 제형으로 제조될 수 있다. 이때 약제학적으로 허용되는 적합한 담체의 예로서는 락토스, 글루코스, 슈크로스, 덱스트로스, 솔비톨, 만니톨, 자일리톨 등의 당류, 옥수수 전분, 감자 전분, 밀 전분 등의 전분류, 셀룰로오스, 메틸셀룰로오스, 에틸셀룰로오스, 나트륨 카르복시메틸셀룰로오스, 하이드록시프로필메틸셀룰로오스 등의 셀룰로오스류, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 마그네슘 스테아레이트, 광물유, 맥아, 젤라틴, 탈크, 폴리올, 식물성유 등을 들 수 있다. 제제화활 경우 필요에 따라 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 및/또는 부형제를 포함하여 제제화할 수 있다.When the pharmaceutical composition of the present invention is prepared in an oral dosage form, powders, granules, tablets, pills, dragees, capsules, liquids, gels, syrups, suspensions, wafers according to methods known in the art with suitable carriers And the like. At this time, examples of suitable pharmaceutically acceptable carriers include starch such as lactose, glucose, sucrose, dextrose, sorbitol, mannitol, xylitol, corn starch, potato starch, wheat starch, starch, cellulose, methylcellulose, ethyl cellulose, Celluloses such as sodium carboxymethylcellulose and hydroxypropylmethylcellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, magnesium stearate, mineral oil, malt, gelatin, talc, polyol, vegetable And the like. In the case of formulation, if necessary, it can be formulated by including diluents and/or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants.
본 발명의 약제학적 조성물이 비경구용 제형으로 제조될 경우, 적합한 담체와 함께 당업계에 공지된 방법에 따라 주사제, 경피 투여제, 비강 흡입제 및 좌제의 형태로 제제화될 수 있다. 주사제로 제제화할 경우 적합한 담체로서는 멸균수, 에탄올, 글리세롤이나 프로필렌 글리콜 등의 폴리올 또는 이들의 혼합물을 사용할 수 있으며, 바람직하게는 링거 용액, 트리에탄올 아민이 함유된 PBS(phosphate buffered saline)나 주사용 멸균수, 5% 덱스트로스 같은 등장 용액 등을 사용할 수 있다. 경피 투여제로 제제화할 경우 연고제, 크림제, 로션제, 겔제, 외용액제, 파스타제, 리니멘트제, 에어롤제 등의 형태로 제제화할 수 있다. 비강 흡입제의 경우 디클로로플루오로메탄, 트리클로로플루오로메탄, 디클로로테트라플루오로에탄, 이산화탄소 등의 적합한 추진제를 사용하여 에어로졸 스프레이 형태로 제제화할 수 있으며, 좌제로 제제화할 경우 그 기제로는 위텝솔(witepsol), 트윈(tween) 61, 폴리에틸렌글리콜류, 카카오지, 라우린지, 폴리옥시에틸렌 소르비탄 지방산 에스테르류, 폴리옥시에틸렌 스테아레이트류, 소르비탄 지방산 에스테르류 등을 사용할 수 있다.When the pharmaceutical composition of the present invention is prepared in a parenteral dosage form, it may be formulated in the form of injections, transdermal administrations, nasal inhalants and suppositories according to methods known in the art with suitable carriers. When formulated as an injectable agent, a suitable carrier may be sterile water, ethanol, polyols such as glycerol or propylene glycol, or mixtures thereof. Preferably, Ringer's solution, PBS (phosphate buffered saline) containing triethanol amine or sterilized for injection Isotonic solutions such as water and 5% dextrose can be used. When formulated as a transdermal dosage form, it can be formulated in the form of ointments, creams, lotions, gels, external solutions, pasta agents, linen agents, aerosols, and the like. For nasal inhalants, dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, etc. can be formulated in the form of an aerosol spray using a suitable propellant, and when formulated as a suppository, Witthesol ( witepsol), tween 61, polyethylene glycols, cacao butter, laurin, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearate, sorbitan fatty acid esters, and the like.
약제학적 조성물의 제제화와 관련하여서는 당업계에 공지되어 있으며, 구체적으로 문헌[Remington's Pharmaceutical Sciences(19th ed., 1995)] 등을 참조할 수 있다. 상기 문헌은 본 명세서의 일부로서 간주 된다.Regarding the formulation of a pharmaceutical composition, it is known in the art, and specifically, refer to Remington's Pharmaceutical Sciences (19th ed., 1995). The above documents are regarded as part of this specification.
본 발명의 약제학적 조성물의 바람직한 투여량은 환자의 상태, 체중, 성별, 연령, 환자의 중증도, 투여 경로에 따라 1일 0.001mg/kg ~ 10g/kg 범위, 바람직하게는 0.001mg/kg ~ 1g/kg 범위일 수 있다. 투여는 1일 1회 또는 수회로 나누어 이루어질 수 있다. 이러한 투여량은 어떠한 측면으로든 본 발명의 범위를 제한하는 것으로 해석되어서는 아니 된다. Preferred dosages of the pharmaceutical compositions of the present invention range from 0.001 mg/kg to 10 g/kg per day, preferably 0.001 mg/kg to 1 g per day, depending on the patient's condition, weight, sex, age, patient severity, and route of administration. /kg range. Administration can be done once a day or divided into several times. Such doses should not be construed as limiting the scope of the invention in any aspect.
본 발명의 조성물은 구체적인 양태에 있어서, 식품 조성물로서 파악할 수 있다.In the specific aspect, the composition of the present invention can be grasped as a food composition.
본 발명의 식품 조성물은 어떠한 형태로도 제조될 수 있으며, 예컨대 차, 쥬스, 탄산음료, 이온음료 등의 음료류, 우유, 요구루트 등의 가공 유류, 껌류, 떡, 한과, 빵, 과자, 면 등의 식품류, 정제, 캡슐, 환, 과립, 액상, 분말, 편상, 페이스트상, 시럽, 겔, 젤리, 바 등의 건강기능식품 제제류 등으로 제조될 수 있다. 또 본 발명의 식품 조성물은 법률상·기능상의 구분에 있어서 제조·유통 시점의 시행 법규에 부합하는 한 임의의 제품 구분을 띨 수 있다. 예컨대 한국 "건강기능식품에관한법률"에 따른 건강기능식품이거나, 한국 "식품위생법"의 식품공전(식약처 고시, 식품의 기준 및 규격)상 각 식품유형에 따른 과자류, 두류, 다류, 음료류, 특수용도식품 등일 수 있다.The food composition of the present invention can be produced in any form, for example, beverages such as tea, juice, carbonated beverages, ionic beverages, processed oils such as milk, yogurt, gums, rice cakes, Chinese medicines, breads, cookies, noodles, etc. It can be made of health functional food formulations such as foods, tablets, capsules, pills, granules, liquids, powders, flakes, pastes, syrups, gels, jelly, bars, and the like. In addition, the food composition of the present invention can be classified into any product as long as it complies with the enforcement regulations at the time of manufacturing and distribution in terms of legal and functional classification. For example, it is a health functional food pursuant to Korea's “Health Functional Food Act” or confectionery, soybean, tea, beverage, etc. according to each food type in the Korea Food and Drug Administration's Food Fair (Korea Food and Drug Administration Notice, Food Standards and Standards). It may be a special purpose food.
본 발명의 식품 조성물에는 그 유효성분 이외에 식품첨가물이 포함될 수 있다. 식품첨가물은 일반적으로 식품을 제조, 가공 또는 보존함에 있어 식품에 첨가되어 혼합되거나 침윤되는 물질로서 이해될 수 있는데, 식품과 함께 매일 그리고 장기간 섭취되므로 그 안전성이 보장되어야 한다. 식품의 제조·유통을 규율하는 각국 법률(한국에서는 "식품위생법"임)에 따른 식품첨가물공전에는 안전성이 보장된 식품첨가물이 성분 면에서 또는 기능 면에서 한정적으로 규정되어 있다. 한국 식품첨가물공전(식약처 고시 "식품첨가물 기준 및 규격)에서는 식품첨가물이 성분 면에서 화학적 합성품, 천연 첨가물 및 혼합 제제류로 구분되어 규정되어 있는데, 이러한 식품첨가물은 기능 면에 있어서는 감미제, 풍미제, 보존제, 유화제, 산미료, 점증제 등으로 구분된다. Food composition of the present invention may include a food additive in addition to the active ingredient. Food additives can be understood as substances that are added to foods and mixed or infiltrated in general in the manufacture, processing, or preservation of foods, and their safety must be ensured because they are consumed daily and for a long time with foods. Food additives in accordance with national laws governing the manufacture and distribution of food ("Food Sanitation Law" in Korea) are limited in terms of ingredients or functions in terms of food additives with guaranteed safety. In the Korean Food Additives Code (Korea Food and Drug Administration's "Food Additive Standards and Standards"), food additives are divided into chemical synthetic products, natural additives, and mixed preparations in terms of ingredients. , Preservatives, emulsifiers, acidulants, thickeners, etc.
감미제는 식품에 적당한 단맛을 부여하기 위하여 사용되는 것으로, 천연의 것이거나 합성된 것 모두 본 발명의 식품 조성물에 사용할 수 있다. 바람직하게는 천연 감미제를 사용하는 경우인데, 천연 감미제로서는 옥수수 시럽 고형물, 꿀, 수크로오스, 프룩토오스, 락토오스, 말토오스 등의 당 감미제를 들 수 있다. Sweeteners are used to impart a moderate sweetness to food, and both natural and synthetic can be used in the food composition of the present invention. Preferably, a natural sweetener is used, and examples of the natural sweetener include sugar sweeteners such as corn syrup solids, honey, sucrose, fructose, lactose, and maltose.
풍미제는 맛이나 향을 좋게 하기 위하여 사용될 수 있는데, 천연의 것과 합성된 것 모두 사용될 수 있다. 바람직하게는 천연의 것을 사용하는 경우이다. 천연의 것을 사용할 경우에 풍미 이외에 영양 강화의 목적도 병행할 수 있다. 천연 풍미제로서는 사과, 레몬, 감귤, 포도, 딸기, 복숭아 등에서 얻어진 것이거나 녹차잎, 둥굴레, 대잎, 계피, 국화 잎, 자스민 등에서 얻어진 것일 수 있다. 또 인삼(홍삼), 죽순, 알로에 베라, 은행 등에서 얻어진 것을 사용할 수 있다. 천연 풍미제는 액상의 농축액이나 고형상의 추출물일 수 있다. 경우에 따라서 합성 풍미제가 사용될 수 있는데, 합성 풍미제로서는 에스테르, 알콜, 알데하이드, 테르펜 등이 이용될 수 있다. Flavoring agents may be used to enhance taste or aroma, and both natural and synthetic ones may be used. Preferably, it is the case of using a natural thing. In addition to flavor, when using natural ones, the purpose of enhancing nutrition can also be combined. As a natural flavoring agent, it may be obtained from apples, lemons, citrus fruits, grapes, strawberries, peaches, or the like, or may be obtained from green tea leaves, perilla, large leaves, cinnamon, chrysanthemum leaves, jasmine, and the like. In addition, those obtained from ginseng (red ginseng), bamboo shoots, aloe vera, and ginkgo can be used. Natural flavors may be liquid concentrates or solid extracts. In some cases, synthetic flavoring agents may be used. As the synthetic flavoring agent, esters, alcohols, aldehydes, terpenes, and the like may be used.
보존제로서는 소르브산칼슘, 소르브산나트륨, 소르브산칼륨, 벤조산칼슘, 벤조산나트륨, 벤조산칼륨, EDTA(에틸렌디아민테트라아세트산) 등이 사용될 수 있고, 또 유화제로서는 아카시아검, 카르복시메틸셀룰로스, 잔탄검, 펙틴 등이 사용될 수 있으며, 산미료로서는 연산, 말산, 푸마르산, 아디프산, 인산, 글루콘산, 타르타르산, 아스코르브산, 아세트산, 인산 등이 사용될 수 있다. 산미료는 맛을 증진시키는 목적 이외에 미생물의 증식을 억제할 목적으로 식품 조성물이 적정 산도로 되도록 첨가될 수 있다.As a preservative, calcium sorbate, sodium sorbate, potassium sorbate, calcium benzoate, sodium benzoate, potassium benzoate, EDTA (ethylenediaminetetraacetic acid), etc. can be used, and as an emulsifier, acacia gum, carboxymethylcellulose, xanthan gum, pectin Etc. can be used, and as acidulant, arithmetic, malic acid, fumaric acid, adipic acid, phosphoric acid, gluconic acid, tartaric acid, ascorbic acid, acetic acid, phosphoric acid and the like can be used. The acidulant may be added so that the food composition has an appropriate acidity for the purpose of suppressing the growth of microorganisms in addition to the purpose of enhancing taste.
점증제로서는 현탁화 구현제, 침강제, 겔형성제, 팽화제 등이 사용될 수 있다.As a thickener, a suspending agent, a sedimentation agent, a gel-forming agent, a swelling agent, etc. can be used.
본 발명의 식품 조성물은 전술한 바의 식품첨가물 이외에, 기능성과 영양성을 보충, 보강할 목적으로 당업계에 공지되고 식품첨가물로서 안정성이 보장된 생리활성 물질이나 미네랄류를 포함할 수 있다.The food composition of the present invention may include physiologically active substances or minerals known in the art for the purpose of supplementing and reinforcing functional and nutritional properties in addition to the food additives as described above, and guaranteed stability as food additives.
그러한 생리활성 물질로서는 녹차 등에 포함된 카테킨류, 비타민 B1, 비타민 C, 비타민 E, 비타민 B12 등의 비타민류, 토코페롤, 디벤조일티아민 등을 들 수 있으며, 미네랄류로서는 구연산칼슘 등의 칼슘 제제, 스테아린산마그네슘 등의 마그네슘 제제, 구연산철 등의 철 제제, 염화크롬, 요오드칼륨, 셀레늄, 게르마늄, 바나듐, 아연 등을 들 수 있다. Examples of such bioactive substances include catechins contained in green tea, vitamins such as vitamin B1, vitamin C, vitamin E, and vitamin B12, tocopherol, dibenzoyl thiamine, and the like, and calcium preparations such as calcium citrate and magnesium stearate as minerals. Magnesium preparations such as iron, iron preparations such as iron citrate, chromium chloride, potassium iodine, selenium, germanium, vanadium, zinc, and the like.
본 발명의 식품 조성물에는 전술한 바의 식품첨가물이 제품 유형에 따라 그 첨가 목적을 달성할 수 있는 적량으로 포함될 수 있다.The food composition of the present invention may include the food additives as described above in an appropriate amount to achieve the purpose of addition according to the product type.
본 발명의 식품 조성물에 포함될 수 있는 기타의 식품첨가물과 관련하여서는 식품위생법에 따른 식품공전이나 식품첨가물 공전을 참조할 수 있다.With regard to other food additives that may be included in the food composition of the present invention, it is possible to refer to food revolutions or food additive revolutions according to the Food Sanitation Act.
전술한 바와 같이, 본 발명에 따르면 상기 화학식 1, 화학식 2 및 화학식 4의 화합물을 이용한 중동호흡기증후군 코로나바이러스에 대한 항바이러스용 조성물을 제공할 수 있다. 본 발명의 조성물은 식품 또는 약품으로 제품화될 수 있다.As described above, according to the present invention, it is possible to provide a composition for antiviral against Coronavirus of the Middle East Respiratory Syndrome using the compounds of Formula 1, Formula 2 and Formula 4. The composition of the present invention can be commercialized as a food or drug.
도 1은 화학식 1 및 화학식 2의 화합물의 중동호흡기증후군 코로나바이러스에 대한 항바이러스 효과를 qRT-PCR을 이용한 바이러스 유전자 정량분석을 통해 나타낸 그래프이다.1 is a graph showing the antiviral effect of the compounds of Formula 1 and Formula 2 on the Middle Eastern Respiratory Syndrome coronavirus through quantitative analysis of viral genes using qRT-PCR.
이하 본 발명을 실시예를 참조하여 설명한다. 그러나 본 발명의 범위가 이러한 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described with reference to Examples. However, the scope of the present invention is not limited to these examples.
실시예: 항바이러스 활성 실험Example: Antiviral activity experiment
실시예 4 : 이미지 기반 중동호흡기증후군 코로나바이러스 억제 효과 분석 (면역 형광 염색 분석법)Example 4 Image-based Middle Eastern Respiratory Syndrome Coronavirus Inhibitory Effect Analysis (Immunofluorescence Dyeing Assay)
<실시예 1> 재료의 준비<Example 1> Preparation of materials
Vero (CCL-81)세포는 ATCC에서 구입하였고, 4 mM L-글루타민과 항생제/항진균제 혼합액을 첨가한 Opti-PRO™ SFM (Gibco, #12309019) 배지에서 배양하였다. 중동호흡기증후군 바이러스는 대한민국 국내 환자에서 분리된 것으로 질병관리본부로부터 분양받아 한국파스퇴르연구소 생물 안전 3등급 (BSL-3) 연구 시설에서 엄격한 관리 하에 사용되었다. 바이러스는 Vero 세포에서 증식되었고, 플라크 어세이를 이용하여 바이러스 역가를 측정하였다. 실험에 쓰인 화합물은 Sigma-Aldrich 社 또는 Tokyo Chemical Industry 社에서 파우더 형태로 구매하여 DMSO 용매에 10 mM 농도로 녹여서 사용하였다.Vero (CCL-81) cells were purchased from ATCC and cultured in Opti-PRO™ SFM (Gibco, #12309019) medium to which 4 mM L-glutamine and antibiotic/antifungal mixture were added. The Middle East Respiratory Syndrome Virus was isolated from patients in Korea and was distributed by the Korea Centers for Disease Control and Prevention and was used under strict management at the Korea Pasteur Research Institute's Biosafety Level 3 (BSL-3) research facility. Viruses were propagated in Vero cells and viral titers were measured using a plaque assay. The compounds used in the experiment were purchased in powder form from Sigma-Aldrich or Tokyo Chemical Industry, and dissolved in DMSO solvent at a concentration of 10 mM.
<실시예 2> 바이러스 증식 억제 효과 실험 - 면역 형광 염색 분석법<Example 2> Virus proliferation inhibitory effect experiment-immunofluorescence staining assay
실험 24시간 전에 384-well black μClear plate의 각 well에 Vero 세포를 1.2 × 104개씩 넣어주었다. 시험 화합물은 중동호흡기증후군 코로나바이러스 감염 직전 각 well에 첨가하였다. 시료 화합물은 10 μM 농도로 처리하였으며, DMSO 농도는 0.5% 이하로 유지되었다. 세포와 시험 화합물이 담긴 플레이트를 생물안전 3등급 실험구역으로 옮긴 후, 바이러스를 0.0625의 MOI(multiplicity of infection)로 감염시키고 24시간 후에 4% 파라포름알데히드로 세포를 고정시킨 다음, 면역 형광 염색을 수행하였다. 토끼에서 분리된 spike에 대한 1차 항체 및 AlexFluorTM 488 형광 2차 항체 (Invitrogen, #A-11008)를 이용하여 바이러스의 감염을 관찰하였고, Hoechst® 33342 (Invitrogen, #H3570) 염색을 통해 세포 생존율을 평가하였다. 이미지는 OperettaTM High-Content Imaging System (PerkinElmer)로 수집하여 한국파스퇴르연구소에서 자체 개발한 Image Mining 3.0 (IM 3.0) 플러그인 소프트웨어로 분석하였다. 2회 반복수행하여 얻은 실험 결과로부터 GraphPad Prism 6 프로그램 (GraphPad Software)을 이용하여 IC50 값 및 CC50 값을 산출하였다. 해당 검색법의 유효성을 평가하는 기준인 Z' factor는 0.97로 나타났으며 중동호흡기증후군 코로나바이러스에 대해 항바이러스 활성을 가지고 있다고 알려진 2개의 화합물 (Chloroquine diphosphate과 Lopinavir)을 사용하여 용량-반응 곡선을 제작하여 유효성을 검증하였다. Twenty four Vero cells were added to each well of a 384-well black μClear plate 24 hours before the experiment. Test compounds were added to each well immediately before infection with the Middle East Respiratory Syndrome Coronavirus. The sample compound was treated at a concentration of 10 μM, and the DMSO concentration was maintained at 0.5% or less. After transferring the cells and the plate containing the test compound to the biosafety level 3 experimental zone, the virus was infected with a multiplicity of infection (MOI) of 0.0625, and after 24 hours, cells were fixed with 4% paraformaldehyde, and then immunofluorescence staining was performed. Was performed. Virus infection was observed using primary antibodies against spikes isolated from rabbits and AlexFluor TM 488 fluorescent secondary antibody (Invitrogen, #A-11008), and cell viability through staining Hoechst® 33342 (Invitrogen, #H3570) Was evaluated. Images were collected with Operetta TM High-Content Imaging System (PerkinElmer) and analyzed with Image Mining 3.0 (IM 3.0) plug-in software developed by Pasteur Korea. The IC 50 value and the CC 50 value were calculated using the GraphPad Prism 6 program (GraphPad Software) from the experimental results obtained by performing the experiment twice. The Z'factor, a criterion for evaluating the effectiveness of the method, was found to be 0.97, and the dose-response curve was calculated using two compounds (Chloroquine diphosphate and Lopinavir) known to have antiviral activity against the Middle East Respiratory Syndrome Coronavirus. Produced and validated.
감염 백분율(PI)은 아래의 수식으로 계산된다.The percentage of infection (PI) is calculated by the formula below.
감염 백분율 (PI) = [1-(INtest - μINmock) / (μINvehicle - μINmock)] × 100%Percentage of infection (PI) = [1-(INtest-μINmock) / (μINvehicle-μINmock)] × 100%
INtest 는 시험 화합물을 처리하고 바이러스를 감염시킨 시험군의 감염율, μINmock은 DMSO를 처리하고 바이러스를 감염시키지 않은 음성 대조군의 감염율, μINvehicle은 DMSO를 처리하고 바이러스를 감염시킨 감염 대조군의 감염율이다. INtest is the infection rate of the test group treated with the test compound and infected with the virus, μINmock is the DMSO treatment, the infection rate of the negative control group without virus infection, and μINvehicle is the DMSO treatment and the infection control group of virus infection.
감염 생존율 (PV)은 아래의 수식으로 계산된다.The survival rate of infection (PV) is calculated by the formula below.
감염 생존율 (PV) = (CNtest / μCNmock)] × 100%Infection survival rate (PV) = (CNtest / μCNmock)] × 100%
CNtest 와 μCNmock 는 각각 시험 화합물을 처리하고 바이러스를 감염시킨 시험군과 DMSO를 처리하고 감염시키지 않은 음성 대조군의 평균 세포수이다. 수치를 표준화한 다음, 바이러스 복제를 50%로 저해시키는 화합물의 농도인 IC50와 숙주 세포의 50%를 사멸시키는 화합물의 농도인 CC50값을 GraphPad Prism 6 프로그램 (GraphPad Software)로 분석하였고, CC50값을 IC50값으로 나누어 선택성 지수 (SI)를 구하였다.CNtest and μCNmock are the mean cell counts of the test group treated with the test compound, the virus-infected group, and the negative control group treated with DMSO and not infected, respectively. After normalizing the values, the IC 50 , which is the concentration of the compound that inhibits viral replication to 50%, and the CC 50 , which is the concentration of the compound that kills 50% of the host cell, were analyzed by the GraphPad Prism 6 program (GraphPad Software), and CC The 50 value was divided by the IC 50 value to obtain the selectivity index (SI).
결과를 아래의 표 1에 나타내었다. 아래의 표에서 최소의 세포 독성으로 최대의 항바이러스 활성을 나타내는 높은 수치의 선택성 지수(SI)를 가지는 것이 높은 항바이러스 효능을 보인다고 해석할 수 있다. n.d.는 약효가 없음을 의미한다.The results are shown in Table 1 below. In the table below, it can be interpreted that having a high level of selectivity index (SI) showing maximum antiviral activity with minimal cytotoxicity shows high antiviral efficacy. n.d. means no effect.
상기 화합물 중 화학식 3의 화합물을 제외한 나머지 모든 화합물이 항바이러스 활성을 보였으며, 특히 화학식 2의 화합물이 높은 항바이러스 활성을 나타냈다. Among the compounds, all the compounds except the compound of Formula 3 showed antiviral activity, and the compound of Formula 2 showed high antiviral activity.
<실시예 3> qRT-PCR에 의한 바이러스 증식 억제 효과 실험<Example 3> Experimental effect of inhibiting virus proliferation by qRT-PCR
3.1 바이러스 감염된 세포의 준비3.1 Preparation of virus-infected cells
실험 24시간 전 24-well plate (Corningⓡ Costarⓡ)의 각 well 에 Vero 세포를 3.0 x 105개 씩 넣어 배양하였다. 시험 화합물을 중동호흡기증후군 코로나바이러스 감염 직전에 각 well 에 첨가하였다. 시험 화합물의 최종 농도는 1, 3, 10, 30 μM 이며, DMSO 농도는 0.5% 이하로 유지되었다. 세포와 시험 화합물이 담긴 플레이트를 생물안전 3등급 실험구역으로 옮긴 후, 바이러스를 0.0625의 MOI 로 감염시켰다. 24시간 후에 세포와 시험 화합물을 PBS로 세척하고 1% beta-mercaptoethanol (Sigma-Aldrich)이 첨가된 RLT buffer (QIAGEN, #79216) 를 넣어 세포를 용해하였다. 24 hours before the experiment, each well of a 24-well plate (Corning ⓡ Costar ⓡ ) was cultured with 3.0 x 10 5 cells each. Test compounds were added to each well immediately before infection with the Middle East Respiratory Syndrome Coronavirus. The final concentration of the test compound was 1, 3, 10, 30 μM, and the DMSO concentration was kept below 0.5%. After transferring the cells and the plate containing the test compound to the biosafety level 3 experimental zone, the virus was infected with a MOI of 0.0625. After 24 hours, the cells and test compounds were washed with PBS, and lysed with 1% beta-mercaptoethanol (Sigma-Aldrich) added RLT buffer (QIAGEN, #79216).
3.2 RNA 추출3.2 RNA extraction
총 RNA는 위에서 얻어낸 세포 용해액으로부터 RNeasyⓡ mini Kit (QIAGEN, #74106)와 제조사 매뉴얼을 이용하여 Diethyl pyrocarbonate (DEPC) 처리한 물에 50μl 부피로 추출하였다. 추출된 RNA 농도는 NanoDropTM One spectrophotometer (Thermo Scientific)를 이용하여 측정하였다.Total RNA was extracted from the cell lysate obtained above by diethyl pyrocarbonate (DEPC) treated water using RNeasy ⓡ mini Kit (QIAGEN, #74106) and manufacturer's manual in a volume of 50 μl. The extracted RNA concentration was measured using a NanoDrop TM One spectrophotometer (Thermo Scientific).
3.3 qRT-PCR3.3 qRT-PCR
감염된 세포의 총 RNA는 multiplex RT-PCR (multiplex real-time reverse-transcription polymerase chain reaction) 실험법을 적용하여 중동호흡기증후군 코로나바이러스의 RNA를 탐지하고, 정량분석 하였다. TOPscriptTM One-step RT-PCR DryMIX kit (Enzynomics, #RT412)을 사용하여 upstream of E gene (upE)양을 측정하였다. 각 25 ul 반응은, TOPscriptTM One-step RT-PCR DryMIX kit에서 제공된 시약 혼합액 튜브에 1 μl의 총 RNA, upE 유전자 발현을 확인하기 위해 논문(Corman VM et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Eurosurveillance 2012; 17:20285)에 사용된 400 nM 농도의 upE-Fwd (GCAACGCGCGATTCAGTT), upE-Rev (GCCTCTACACGGGACCCATA) 프라이머쌍과 upE-Prb (6-carboxyfluorescein [FAM]- CTCTTCACATAATCGCCCCGAGCTCG-6-carboxy-N,N,N,N´-tetramethylrhodamine [TAMRA]) 프로브를 첨가하여 반응시켰다. 내부 대조군으로서 GAPDH 유전자 발현양 측정을 위하여 400 nM 농도의 GAPDH-Fwd (GAAGGTGAAGGTCGGAGTCAAC), GAPDH-Rev (CAGAGTTAAAAGCAGCCCTGGT) 프라이머쌍과 GAPDH-Prb (6-carboxy-4',5'-dichloro-2',7'- dimethoxyfluorescein[JOE]-TTTGGTCGTATTGGGCGCT-6-carboxy-N,N,N,N´-tetramethylrhodamine[TAMRA]) 프로브를 첨가하여 반응시켰다. 역전사 반응과 유전자 증폭은 ViiATM 7 Real-Time PCR System (Thermo Scientific)을 이용하여 50℃에 30분, 95℃에 3분, (95℃에 30초, 58℃에 1분)×40사이클로 진행하였다. 측정된 중동호흡기증후군 코로나바이러스의 upE 유전자 발현양은 GAPDH 양으로 보정하여 Comparative CT Method (ΔΔCT Method)로 분석하였다. 참고로 E 유전자는 외피단백질 유전자로, E 유전자의 상위 영역(upstream of E gene)의 발현 정도는 바이러스의 증식 정도를 보여주는 지표로 사용될 수 있다(Corman VM et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Eurosurveillance 2012; 17:20285).The total RNA of the infected cells was detected using the multiplex RT-PCR (multiplex real-time reverse-transcription polymerase chain reaction) method to detect and quantify the RNA of the Middle East respiratory syndrome coronavirus. The amount of upstream of E gene (upE) was measured using a TOPscript TM One-step RT-PCR DryMIX kit (Enzynomics, #RT412). Each 25 ul reaction is a paper to confirm the expression of 1 μl total RNA and upE gene in a reagent mixture tube provided by TOPscript TM One-step RT-PCR DryMIX kit (Corman VM et al. Detection of a novel human coronavirus by real -time reverse-transcription polymerase chain reaction.UpE-Fwd (GCAACGCGCGATTCAGTT), upE-Rev (GCCTCTACACGGGACCCATA) primer pair and upE-Prb (6-carboxyfluorescein [FAM]-) at 400 nM concentration used in Eurosurveillance 2012; 17:20285) CTCTTCACATAATCGCCCCGAGCTCG-6-carboxy-N,N,N,N´-tetramethylrhodamine [TAMRA]) probe was added to react. GAPDH-Fwd (GAAGGTGAAGGTCGGAGTCAAC), GAPDH-Rev (CAGAGTTAAAAGCAGCCCTGGT) primer pair and GAPDH-Prb (6-carboxy-4',5'-dichloro-2',7 at 400 nM concentration for the measurement of GAPDH gene expression as an internal control. '- dimethoxyfluorescein[JOE]-TTTGGTCGTATTGGGCGCT-6-carboxy-N,N,N,N´-tetramethylrhodamine[TAMRA]) probe was added to react. Reverse transcription reaction and gene amplification were performed using ViiA TM 7 Real-Time PCR System (Thermo Scientific) at 50°C for 30 minutes, 95°C for 3 minutes, (95°C for 30 seconds, and 58°C for 1 minute) x 40 cycles. Did. The measured upE gene expression level of the Middle Eastern Respiratory Syndrome Coronavirus was corrected with the amount of GAPDH and analyzed by Comparative CT Method (ΔΔCT Method). For reference, the E gene is an envelope protein gene, and the expression level of the upstream of the E gene can be used as an indicator of the degree of virus proliferation (Corman VM et al. Detection of a novel human coronavirus by real -time reverse-transcription polymerase chain reaction Eurosurveillance 2012; 17:. 20285).
3.4 결과3.4 Results
결과를 도 1에 나타내었다. 본 실험에서는 화학식 1 및 화학식 2의 화합물을 대표적으로 사용하였으며, 도 1을 참조하여 보면 이들 화합물들 모두 농도 의존적으로 E 유전자의 상위 영역의 발현을 억제함으로 보여준다.The results are shown in FIG. 1. In this experiment, the compounds of Formula 1 and Formula 2 are typically used, and referring to FIG. 1, all of these compounds are shown to inhibit the expression of the upper region of the E gene in a concentration-dependent manner.
Claims (4)
A composition for antiviral against Middle East Respiratory Syndrome Coronavirus (MERS-CoV), comprising any one of the compounds of Formula 1, Formula 2 and Formula 4, its prodrug, its solvate or its hydrate as an active ingredient.
상기 항바이러스는 중동호흡기증후군의 치료, 예방 또는 증상 경감인 것을 특징으로 하는 조성물.
According to claim 1,
The anti-viral is a composition characterized in that the treatment, prevention or symptom relief of the Middle East Respiratory Syndrome.
상기 조성물은 약제학적 조성물인 것을 특징으로 하는 조성물.
The method according to claim 1 or 2,
The composition is characterized in that the pharmaceutical composition.
상기 조성물은 식품 조성물인 것을 특징으로 하는 조성물.
The method according to claim 1 or 2,
The composition is characterized in that the food composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180159448A KR102135116B1 (en) | 2018-12-11 | 2018-12-11 | Antiviral Composition for Middle East Respiratory Syndrome Coronavirus Using Chloroxine or Analogues Thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180159448A KR102135116B1 (en) | 2018-12-11 | 2018-12-11 | Antiviral Composition for Middle East Respiratory Syndrome Coronavirus Using Chloroxine or Analogues Thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20200071573A true KR20200071573A (en) | 2020-06-19 |
KR102135116B1 KR102135116B1 (en) | 2020-07-17 |
Family
ID=71137089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180159448A KR102135116B1 (en) | 2018-12-11 | 2018-12-11 | Antiviral Composition for Middle East Respiratory Syndrome Coronavirus Using Chloroxine or Analogues Thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102135116B1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1908548A1 (en) * | 1968-02-29 | 1970-11-05 | Warner Lambert Co | Quinoline derivatives |
US20060269485A1 (en) * | 2002-11-29 | 2006-11-30 | Foamix Ltd. | Antibiotic kit and composition and uses thereof |
CN103705516A (en) * | 2013-12-11 | 2014-04-09 | 武汉威立得生物医药有限公司 | Application of chloroxine in preparing drug for treating or preventing influenza virus infections |
-
2018
- 2018-12-11 KR KR1020180159448A patent/KR102135116B1/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1908548A1 (en) * | 1968-02-29 | 1970-11-05 | Warner Lambert Co | Quinoline derivatives |
US20060269485A1 (en) * | 2002-11-29 | 2006-11-30 | Foamix Ltd. | Antibiotic kit and composition and uses thereof |
CN103705516A (en) * | 2013-12-11 | 2014-04-09 | 武汉威立得生物医药有限公司 | Application of chloroxine in preparing drug for treating or preventing influenza virus infections |
Also Published As
Publication number | Publication date |
---|---|
KR102135116B1 (en) | 2020-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11642387B2 (en) | Composition for preventing or inhibiting influenza virus infection, containing ginseng berry polysaccharides | |
KR102135106B1 (en) | Antiviral Composition for Middle East Respiratory Syndrome Coronavirus | |
KR102054597B1 (en) | Composition for Improvement of Exercise Performance Using an Extract of Ishige okamurae | |
KR101708833B1 (en) | Anti-viral composition comprising curcumin | |
JP2016088845A (en) | Anti-fatigue and immune promoting food composition | |
KR101924389B1 (en) | Composition for improving male sexual function using ginsenoside compound K and a maca extract | |
KR102135116B1 (en) | Antiviral Composition for Middle East Respiratory Syndrome Coronavirus Using Chloroxine or Analogues Thereof | |
KR102343728B1 (en) | Composition for prevention or treatment of sepsis or septic shock comprising maslinic acid | |
KR101964080B1 (en) | Composition for Improvement of Exercise Performance Using Novel Compound hexadecaphlorethol Isolated from Ishige okamurae | |
Ogura et al. | Evaluation of an edible blue-green alga, Aphanothece sacrum, for its inhibitory effect on replication of herpes simplex virus type 2 and influenza virus type A | |
KR101995067B1 (en) | Composition comprising natural mineral extract as active ingredient for improving exercise performance by enhancing energy metabolism | |
KR101247802B1 (en) | Composition for preventing and treating inflammatory disease comprising piperine or pharmaceutically acceptable salt thereof as an active ingredient | |
WO2021187670A1 (en) | Composition for alleviating coronavirus infection using raloxifene | |
KR102541320B1 (en) | Composition for improving of coronavirus infection symptoms using raloxifene | |
KR101770395B1 (en) | Composition for preventing or treating of autophagy mediated disease comprising conessine as an active ingredient | |
KR20180045595A (en) | Composition for Improving Liver Function Using an Extract of Black Radish | |
KR101787954B1 (en) | Pharmaceutical composition for treating and inhibiting metastasis of glioblastoma comprising protopanaxadiols compound | |
KR102528545B1 (en) | Antiviral composition | |
KR102576731B1 (en) | Antiviral composition | |
KR20190058394A (en) | Antimicrobial, antiparasite, antiviral and antioxidant compositions of fish comprising Rhus verniciflua lignum extract | |
KR102311887B1 (en) | Composition comprising Sargassum Horner extract for preventing or treating liver disease | |
KR102185945B1 (en) | Antiviral composition | |
KR101563219B1 (en) | Composition comprising carnosic acid having anti-Respiratory syncytial virus activity | |
KR102596373B1 (en) | Antiviral composition | |
KR102153250B1 (en) | Anti-inflammatory composition of blueberries containing chlorogenic acid as a standard |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |